- entecavir monohydrate
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.
The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/06/343/003, EU/1/06/343/001, EU/1/06/343/006.
Baraclude 0.5 mg film coated tablets
Package leaflet: Information for the user
Baraclude 0.5 mg film-coated tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Baraclude is and what it is used for
2. What you need to know before you take Baraclude
3. How to take Baraclude
4. Possible side effects
5. How to store Baraclude
6. Contents of the pack and other information
1. What BARACLUDE is and what it is used for
Baraclude tablets are anti-viral medicines, used to treat chronic (long term) hepatitis B virus (HBV) infection in adults. Baraclude can be used in people whose liver is damaged but still functions properly (compensated liver disease) and in people whose liver is damaged and does not function properly (decompensated liver disease).
Baraclude tablets are also used to treat chronic (long term) HBV infection in children and adolescents aged 2 years to less than 18 years. Baraclude can be used in children whose liver is damaged but still functions properly (compensated liver disease).
Infection by the hepatitis B virus can lead to damage to the liver. Baraclude reduces the amount of virus in your body, and improves the condition of the liver.
2. What you need to know before you take BARACLUDE
Do not take Baraclude
Warning and precautions
Talk to your doctor or pharmacist before taking Baraclude
Children and adolescents
Baraclude should not be used for children below 2 years of age or weighing less than 10 kg.
Other medicines and Baraclude
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Baraclude with food and drink
In most cases you may take Baraclude with or without food. However, if you have had a previous treatment with a medicine containing the active substance lamivudine you should consider the following. If you were switched over to Baraclude because the treatment with lamivudine was not successful, you should take Baraclude on an empty stomach once daily. If your liver disease is very advanced, your doctor will also instruct you to take Baraclude on an empty stomach. Empty stomach means at least 2 hours after a meal and at least 2 hours before your next meal.
Children and adolescents (from 2 to less than 18 years of age) can take Baraclude with or without food.
Pregnancy, breast-feeding and fertility
Tell your doctor if you are pregnant or planning to become pregnant. It has not been demonstrated that Baraclude is safe to use during pregnancy. Baraclude must not be used during pregnancy unless specifically directed by your doctor. It is important that women of childbearing age receiving treatment with Baraclude use an effective method of contraception to avoid becoming pregnant.
You should not breast-feed during treatment with Baraclude. Tell your doctor if you are breast-feeding. It is not known whether entecavir, the active ingredient in Baraclude, is excreted in human breast milk.
Driving and using machines
Dizziness, tiredness (fatigue) and sleepiness (somnolence) are common side effects which may impair your ability to drive and use machines. If you have any concerns consult your doctor.
Baraclude contains lactose
This medicinal product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
3. How to take BARACLUDE
Not all patients need to take the same dose of Baraclude.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
For adults the recommended dose is either 0.5 mg or 1 mg once daily orally (by mouth).
Your dose will depend on:
For children and adolescents (from 2 to less than 18 years of age), your child's doctor will decide the right dose based on your child's weight. The Baraclude oral solution is recommended for patients weighing from 10 kg to 32.5 kg.Children weighing at least 32.6 kg may take the oral solution or the 0.5 mg tablet. All dosing will be taken once daily orally (by mouth). There are no recommendations for Baraclude in children less than 2 years of age or weighing less than 10 kg.
Your doctor will advise you on the dose that is right for you. Always take the dose recommended by your doctor to ensure that your medicine is fully effective and to reduce the development of resistance to treatment. Take Baraclude as long as your doctor has told you. Your doctor will tell you if and when you should stop the treatment.
Some patients must take Baraclude on an empty stomach (see Baraclude with food and drink in Section 2). If your doctor instructs you to take Baraclude on an empty stomach, empty stomach means at least 2 hours after a meal and at least 2 hours before your next meal.
If you take more Baraclude than you should
Contact your doctor at once.
If you forget to take Baraclude
It is important that you do not miss any doses. If you miss a dose of Baraclude, take it as soon as possible, and then take your next scheduled dose at its regular time. If it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not take a double dose to make up for a forgotten dose.
Do not stop Baraclude without your doctor’s advice
Some people get very serious hepatitis symptoms when they stop taking Baraclude. Tell your doctor immediately about any changes in symptoms that you notice after stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Patients treated with Baraclude have reported the following side effects:
common (at least 1 in 100 patients): headache, insomnia (inability to sleep), fatigue (extreme tiredness), dizziness, somnolence (sleepiness), vomiting, diarrhoea, nausea, dyspepsia (indigestion), and increased blood levels of liver enzymes.
uncommon (at least 1 in 1,000 patients): rash, hair loss.
rare (at least 1 in 10,000 patients): severe allergic reaction.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below)By reporting side effects you can help provide more information on the safety of this medicine.
or search for MHRA Yellow Card in the Google Play or Apple App Store
5. How to store BARACLUDE
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle, blister or carton after EXP. That expiry date refers to the last day of that month.
Blister packs: do not store above 30°C. Store in the original carton.
Bottle packs: do not store above 25°C. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Baraclude contains
What Baraclude looks like and contents of the pack
The film-coated tablets (tablets) are white to off-white and triangular-shaped. They are marked with “BMS” on one side and “1611” on the other. Baraclude 0.5 mg film-coated tablets are supplied in cartons containing 30 x 1 or 90 x 1 film-coated tablet (in unit-dose blisters) and in bottles containing 30 film-coated tablets.
Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
This leaflet was last revised in April 2019
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.